Australian weight loss + bariatric FAQ

Sleeve gastrectomy $18,000–$25,000 fully self-pay. With private health insurance: $8,000–$18,000 out-of-pocket. Roux-en-Y gastric bypass $20,000–$30,000 fully self-pay. Adelaide is consistently Australia's lowest-cost capital. Public hospital bariatric surgery exists but 2–5 year waitlists are typical. See our health-fund coverage guide.

Australian guidelines: BMI 35+ with weight-related health conditions (Type 2 diabetes, hypertension, sleep apnoea, severe joint disease, NASH), OR BMI 40+ regardless. You'll need assessment by a bariatric surgeon, dietitian, psychologist + sometimes endocrinologist. Most surgeons require evidence of previous medical weight-loss attempts. See our BMI calculator.

Sleeve gastrectomy is ~60–70% of Australian primary bariatric procedures — best for most adults with BMI 35–50, minimal anatomical complexity. Roux-en-Y gastric bypass (15–20%) is recommended for severe reflux + diabetes-dominant patients. Lap-band is now rarely performed as a primary procedure — long-term data is poor + revision rates high. Mini-bypass / SADI-S are advanced procedures at specialist centres only.

Australia + NZ Metabolic and Obesity Surgery Society — the peak professional society for bariatric surgeons. Membership requires FRACS qualification, current bariatric practice + adherence to ANZMOSS Position Statements. ~85–90% of high-volume Australian bariatric surgeons are members. Strongest professional credential signal short of AHPRA registration.

Documented volume-outcome relationship. Surgeons performing 100+ sleeve gastrectomies / bypasses per year have measurably better complication rates than surgeons performing under 50/year. Ask directly: "How many of this specific procedure have you personally done in the last 12 months?" A high-volume surgeon will answer comfortably. A vague answer is a signal.

For bariatric surgery, hospital matters as much as surgeon. Look for: dedicated bariatric ward, in-house bariatric dietitian + psychologist, 24/7 anaesthetist coverage with bariatric experience, established leak-rescue + bleed-rescue protocols. Epworth Eastern (Australia's largest dedicated bariatric centre), Westmead Private, Hollywood Private + similar are the gold-standard hospitals. See our pre-op checklist.

Wegovy (semaglutide, Novo Nordisk) is a once-weekly GLP-1 agonist. Trials show 15% body weight loss over 68 weeks. Mounjaro (tirzepatide, Eli Lilly) is a once-weekly dual GIP/GLP-1 agonist. Trials show 21% body weight loss over 72 weeks — currently a TGA-approved weight-management medicine available in Australia. Both cost $400–$600/month privately. Side effects (nausea, fatigue) tend to be milder with Mounjaro.

TGA-approved for BMI 27+ with weight-related comorbidities (Type 2 diabetes, hypertension, sleep apnoea, dyslipidaemia) OR BMI 30+. PBS subsidy applies to a narrow subset (Type 2 diabetes only currently). Most patients pay full private cost. See our BMI calculator.

$400–$600/month privately depending on dose (2.5mg through 15mg). Higher doses are not more expensive — pricing is per pen, not per mg. Annual cost $5,000–$7,000 — comparable to bariatric surgery's break-even within 3–4 years if continued indefinitely. See our cost calculator.

Yes — Juniper, Pilot, Mosh, Eucalyptus, Hers all offer telehealth GLP-1 prescriptions for $300–$500/month including coaching + dietitian support. Independent reviews show similar weight-loss outcomes to in-person clinics (medication is the primary driver). Best for motivated self-starters; in-person clinics suit patients with complex comorbidities or who want closer follow-up.

Most prescribers wash out 1–2 weeks then start Mounjaro at 2.5mg + titrate. Don't self-switch — coordinate with prescriber. Same-day overlap is not advised. See our GLP-1 starter kit + side-effects timeline.

Periodic shortages affect both Wegovy + Mounjaro globally + Australia. TGA publishes shortage notices. Larger compound pharmacies + telehealth providers tend to manage supply better than small independents. See our supply tracker for current state by chemist.

AHPRA Specialist Register (mandatory surgeon registration). ANZMOSS member directory. TGA-approved supply chain data for medications. Clinic-published cost data. See our methodology + press kit for downloadable CSVs.

Yes — entirely free. No sign-up, no email capture, no paid placements. We make money via display advertising + a (planned) premium provider profile tier. Rankings are not for sale.

No. Operated by Boring Ventures Pty Ltd (ABN 67 671 943 758), an independent Australian company. No commercial relationship with Eli Lilly, Novo Nordisk or any specific clinic. All ranking + comparison logic is published transparently in our methodology.